OBJECTIVE: Granulocyte colony-stimulating factor (G-CSF) is a cytokine that is clinically used to treat neutropenia. G-CSF also has non-hematopoietic functions and could potentially be used to treat neuronal injury. To confirm the safety and feasibility of G-CSF administration for acute spinal cord injury (SCI), we have initiated a phase I/IIa clinical trial of neuroprotective therapy using G-CSF. METHODS: The trial included a total of 16 SCI patients within 48 h of onset. In the first step, G-CSF (5 μg/kg/day) was intravenously administered for 5 consecutive days to 5 patients. In the second step, G-CSF (10 μg/kg/day) was similarly administered to 11 patients. We evaluated motor and sensory functions of patients using the American Spinal Cord Injury Association (ASIA) score and ASIA impairment scale (AIS) grade. RESULTS: In all 16 patients, neurological improvement was obtained after G-CSF administration. AIS grade increased by one step in 9 of 16 patients. A significant increase in ASIA motor scores was detected 1 day after injection (P < 0.01), and both light touch and pin prick scores improved 2 days after injection (P < 0.05) in the 10 μg group. No severe adverse effects were observed after G-CSF injection. CONCLUSION: These results indicate that intravenous administration of G-CSF (10 μg/kg/day) for 5 days is essentially safe, and suggest that some neurological recovery may occur in most patients. We suggest that G-CSF administration could be therapeutic for patients with acute SCI.
OBJECTIVE:Granulocyte colony-stimulating factor (G-CSF) is a cytokine that is clinically used to treat neutropenia. G-CSF also has non-hematopoietic functions and could potentially be used to treat neuronal injury. To confirm the safety and feasibility of G-CSF administration for acute spinal cord injury (SCI), we have initiated a phase I/IIa clinical trial of neuroprotective therapy using G-CSF. METHODS: The trial included a total of 16 SCI patients within 48 h of onset. In the first step, G-CSF (5 μg/kg/day) was intravenously administered for 5 consecutive days to 5 patients. In the second step, G-CSF (10 μg/kg/day) was similarly administered to 11 patients. We evaluated motor and sensory functions of patients using the American Spinal Cord Injury Association (ASIA) score and ASIA impairment scale (AIS) grade. RESULTS: In all 16 patients, neurological improvement was obtained after G-CSF administration. AIS grade increased by one step in 9 of 16 patients. A significant increase in ASIA motor scores was detected 1 day after injection (P < 0.01), and both light touch and pin prick scores improved 2 days after injection (P < 0.05) in the 10 μg group. No severe adverse effects were observed after G-CSF injection. CONCLUSION: These results indicate that intravenous administration of G-CSF (10 μg/kg/day) for 5 days is essentially safe, and suggest that some neurological recovery may occur in most patients. We suggest that G-CSF administration could be therapeutic for patients with acute SCI.
Authors: P Anderlini; D Przepiorka; D Seong; P Miller; J Sundberg; B Lichtiger; F Norfleet; K W Chan; R Champlin; M Körbling Journal: Transfusion Date: 1996-07 Impact factor: 3.157
Authors: W-R Schäbitz; R Kollmar; M Schwaninger; E Juettler; J Bardutzky; M N Schölzke; C Sommer; S Schwab Journal: Stroke Date: 2003-02-13 Impact factor: 7.914
Authors: M Murata; M Harada; S Kato; S Takahashi; H Ogawa; S Okamoto; S Tsuchiya; H Sakamaki; Y Akiyama; Y Kodera Journal: Bone Marrow Transplant Date: 1999-11 Impact factor: 5.483
Authors: M B Bracken; M J Shepard; W F Collins; T R Holford; W Young; D S Baskin; H M Eisenberg; E Flamm; L Leo-Summers; J Maroon Journal: N Engl J Med Date: 1990-05-17 Impact factor: 91.245
Authors: Nureddin Ashammakhi; Han-Jun Kim; Arshia Ehsanipour; Rebecca D Bierman; Outi Kaarela; Chengbin Xue; Ali Khademhosseini; Stephanie K Seidlits Journal: Tissue Eng Part B Rev Date: 2019-10-23 Impact factor: 6.389
Authors: Stephanie Wallner; Sebastian Peters; Claudia Pitzer; Herbert Resch; Ulrich Bogdahn; Armin Schneider Journal: Front Cell Dev Biol Date: 2015-08-07